21 results on '"Mahabadi, V"'
Search Results
2. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
- Author
-
Holman, Rr, Bethel, Ma, Mentz, Rj, Thompson, Vp, Lokhnygina, Y, Buse, Jb, Chan, Jc, Choi, J, Gustavson, Sm, Iqbal, N, Maggioni, Ap, Marso, Sp, Öhman, P, Pagidipati, Nj, Poulter, N, Ramachandran, A, Zinman, B, Hernandez, Af, EXSCEL Study Group, : Califf RM, Patel, R, George, J, Sourij, H, Wong, Yw, Hannan, K, Sellers, Ma, Gottlieb, P, Lavender, P, Leloudis, D, Meadows, Y, Larson, D, Anderson, H, Elkins, M, Stone, A, Tisch, A, Perkins, L, Sanders, K, Campbell, C, Kennedy, I, Heal, P, Masterson, M, Darbyshire, J, Mumtaz, L, Athwal, R, Ferch, A, Batra, P, Durborow, L, Vincent, J, Woodall, A, Flanagan, T, Katona, B, Reicher, B, Pozzi, E, Oulhaj, A, Coleman, R, Rouleau, Jl, Pocock, Sj, Gorelick, F, Mcmurray, J, Riddle, M, Gagel, R, Collier, T, Markovic, T, Kong, Aps, Hian, Sk, Scott, R, Panelo, A, Yoon, Kh, Sheu, W, Sritara, P, Linong, J, Pan, C, Yong, H, Schernthaner, G, Mathieu, C, Tankova, T, Widimsky, P, Hanefeld, M, Keltai, M, Wainstein, J, del Prato, S, Pirags, V, Jakuboniene, N, Kooy, A, Dziemidok, P, Veresiu, Ia, Dreval, Av, Murin, J, Torello, Al, Sattar, N, Parkhomenko, O, Omar, M, Diaz, R, Lopes, R, Lanas, F, Urina Triana, M, Leiva-Pons, Jl, Aguliera, D, Bergenstal, R, Goodman, S, Yale, Jf, Caterson, I, Weng, J, Hu, D, Junbo, G, Zannad, F, Anoop, M, Ambrish, M, Gallegos, Ja, Green, Jb, Akerblom, A, Alexander, K, Al-Khatib, S, Armaganijan, L, Barros, P, Batit, M, Bernacki, G, Bernandez, S, Bloomfield, G, Clausen, E, De Souza Brito, F, Devore, A, Dombrowski, K, Eapen, Z, Gellad, Z, George, D, Guimaraes, P, Halim, S, Harrison, R, Hawes, J, Hess, C, Hyland, K, Jackson, L, Jones, S, Jordan, D, Katz, M, Kong, D, Koshizaka, M, Lakey, W, Leblanc, T, Leonardi, S, Luo, N, Mahaffey, K, Mandawat, A, Mehta, R, Melloni, C, Morse, M, Pagidpati, N, Patel, C, Patel, K, Pokorney, S, Posvic, T, Rao, M, Roe, M, Shah, B, Tillmann, H, Truffa, A, Zazula, A, Zeitler, E, Sicer, M, Ulla, Mr, Maffei, L, Klyver, Mi, Calella, P, Alvarisqueta, A, De La Fuente RL, Aizenberg, D, Roque, F, Cruciani, A, Frechtel, G, Gelersztein, E, Villarino, A, Mallagray, M, Nardone, L, Zaidman, C, Novaretto, L, Bartolacci, I, de Salvo, M, Delcourt, C, Crimmins, D, Jackson, R, O’Neal, D, Colman, P, Jeffries, W, Mah, Pm, Wittert, G, Proietto, J, Amerena, J, Marks, S, Tan, R, Colquhoun, D, Pieber, T, Drexel, H, Prager, R, Schnack, C, Hoppichler, F, Fasching, P, Francesconi, C, Luger, A, Schoenherr, Hr, Ebenbichler, C, Paulweber, B, Shernthaner, G, Verhaegen, A, Vanuytsel, J, Thissen, Jp, e Silva P, Barros, Gonzaga, C, Borges, J, Hissa, M, Rea, R, Rossi, P, Chacra, A, Eliaschewitz, F, Garbelini, B, Felicio, J, Rassi, N, Rossi, F, Nunes dos Santos, M, e Farias F, Bandeira, Lisboa, H, e Forti A, Costa, Saraiva, Jk, Kovacheva, S, Levterov, G, Sheinkova, G, Ilieva, E, Lyubenova, L, Damyanova, V, Gushterova, V, Mincheva, L, Illiev, D, Ivanov, V, Bobeva, R, Nikitov, Z, Shumkova, R, Lefterov, In, Zaharieva, S, Videva, V, Yakov, A, Cheung, S, Elliott, T, Mehta, P, Ross, S, Sigal, R, Woo, V, Jaffer, S, Kuritsky, R, Bell, A, Dumas, R, Gosselin, G, Robitaille, Y, Greenspoon, A, Lochnan, H, Tytus, R, Leiter, L, Pandey, A, Punthakee, Z, Dube, F, Sigalas, J, Pearce, M, Woodford, T, Paul, P, Bourgeois, R, Conway, R, Mazza, G, Hatheway, R, Misterski, J, Raffo, C, Olivares, C, Godoy, J, Potthoff, S, Santibañez, C, Larenas Yanez GJ, Gu, W, Shen, F, Ma, J, Guo, X, Li, Q, Du, Y, Hu, J, Ji, L, Li, Y, Deng, H, Feng, Y, Liu, L, Mu, Y, Ma, C, Qu, S, Wang, J, Wang, Y, Yuan, Z, Zhang, L, Zhou, S, Yang, T, Dong, Y, Liu, D, Coronel Arroyo, J, Perez Amador, G, Botero Lopes, R, Jaramilo, C, Orozco Linares, A, Cure Cure CA, Hernandez Triana, E, Molina de Salazar DI, Marin, Cr, Jaramilo Gomez CJ, Kellinerova, I, Adamkova, V, Krami, P, Brychta, T, Havelkova, J, Pantikova, K, Schoper, F, Pohl, W, Schumm-Draeger, Pm, Julius, U, Tschöpe, D, Hamann, A, Seissler, J, Schellong, S, Rose, L, Becker, B, Linn, T, Oerter, Em, Strotmann, Hj, Mölle, A, Pfutzner, A, Forst, T, Schäufele, T, Mugge, A, Lehrke, M, Meyer-Pannwitt, U, Mehling, H, Simon-Wagner, I, Schenkenberger, I, Busch, K, Hermes, S, Milek, K, Landers, B, Grueneberg, M, Braun, M, Nothroff, J, Kamke, W, Hergdt, G, Duengen, Hd, Kleinertz, K, Kuesters, D, Boenninghoff, Ah, Appel, Kf, Schaefer, A, Bieler, T, Ozaki, R, Luk, Aoy, Chu, Dw, Cheung-Wong, Mm, Siu, Dc, Yan, Bpy, Kung, K, Wong, Sys, Tsang, Cc, Yeung, Vt, Cheung, Bm, Tse, Hf, Hodi, G, Nagy, K, Lippai, J, Takacs, J, Fulop, T, Gaal, Z, Pauker, Z, Foldesi, I, Simon, J, Oroszan, T, Futo, L, Bezzegh, K, Nagy, A, Vandorfi, G, Kiss, J, Kesmarki, N, Kis, E, Papp, A, Kovacs, A, Szakal, I, Palinkas, A, Czegany, Z, Voros, P, Reiber, I, Kerenyi, Z, Dezso, E, Wittman, I, Penzes, J, Ples, Z, Taller, A, Farago, K, Kis, Jt, Zilahi, Z, Molnar, M, Barkai, L, Mileder, M, Szentpeteri, I, Peterfai, E, Lovasz, O, Mosenzon, O, Minuchin, O, Jaffe, A, Vishlitsky, V, Shimon, I, Bashkin, A, Stern, N, Elias, N, Bental, T, Butnaru, A, Lewis, B, Adawi, F, Nseir, W, Klainman, E, Herskovits, T, Cignarelli, M, Rotella, Cm, Ambrosio, G, Pozzilli, P, Genovese, S, Cavarape, A, Salvioni, A, Sokolova, J, Strautina, I, Teterovska, D, Stalte, V, Pastare, S, Leitane, I, Lagzdina, L, Andersone, I, Eglite, R, Stelmane, I, Levinger, A, Barsiene, L, Sulskiene, M, Varanauskiene, E, Danyte, E, Urbanaviciene, E, Urbanavicius, V, Zabuliene, L, Juskiene, R, Velaviciene, A, Kakariekiene, V, Augusteniene, A, Velickiene, D, Lasiene, J, Dauksiene, D, Caponis, J, Tan, At, Ramanathan, L, Hassan, Mra, Tan, F, Ong, Tk, Foo, Sh, Ghani, Ra, Cheah, Wk, Sanchez Mijangos JH, Cabrera Jardines, R, Barrientos Perez, M, Sauque Reyna, L, Alcocer Gamba MA, Villeda Espinosa, E, Tamez Perez HE, De La Garza Hernandez NE, Lopes, Sm, Ramirez Diaz SP, Reyes Sanchez, R, Márquez-Rodriguez, E, Köse, V, Voors-Pette, C, Oldenburg-Ligtenberg, Pc, van Kempen WW, Cox, K, Hoogendyk, J, Swinkels-Diepenmaat, L, Rojas-Lingan, G, Kentgens, S, Schipperen, S, de Valk HW, Swart, H, van Bemmel, B, Hoogslag, Pam, Diamant, M, Serné, Eh, Hamer, A, Wilson, S, Fisher, N, Dixon, P, Chaudhri, O, Crawford, V, Quinn, D, Nirmalaraj, K, Dunn, P, Gillies, J, Cutfield, R, Krebs, J, Helm, C, Kerr, J, Pryke, J, Ebo, G, Denopol, M, Ang, E, Uy, N, Jimeno, C, Mirasoi, R, Paz Pacheco, E, Custodio, M, Nicodemus, N Jr, Catindig, Ea, Magno, M, Tirador, L, Cylkowska, B, Stasinksa, T, Silwinska, T, Sroka, M, Piepiorka, M, Korzeniak, R, Mirecka, H, Zaluska, R, Pupek-Musialik, D, Homenda, W, Grabowska, A, Okopien, B, Niegowska, J, Pogorzelska, H, Mikolajczyk-Swatko, A, Sikorski, M, Sowinski, D, Tahk, Sj, Kim, Yn, Nam, Cw, Rim, Sj, Kim, Cj, Choi, Km, Lee, Ik, Kim, Ij, Namgung, J, Moon, Kw, Kim, Ks, Oh, Bh, Lee, Wy, Choi, Sh, Kim, Es, Moon, S, Mindrescu, Nm, Aron, G, Graur, M, Hancu, N, Mlitaru, C, Nafornita, V, Szilagyi, I, Popa, Ar, Angelescu, Lm, Negrisanu, Gd, Zaharie, Dg, Culman, Mi, Vacaru, G, Munteanu, M, Constantinescu, S, Tivadar, S, Dreval, A, Barbarash, O, Strongin, L, Dogadin, S, Suplotova, L, Izmozherova, N, Marasaev, V, Khokhlov, A, Repin, A, Turova, E, Bondar, I, Samoylova, Y, Sherenkov, A, Smolenskaya, O, Zrahevskiy, K, Koshelskaya, O, Obrezan, A, Dzupina, A, Stevlik, J, Buganova, I, Pella, D, Vinanska, D, Jascur, J, Micko, K, Sosovec, D, Philippiova, A, Olexa, P, Fedacko, J, Selecky, J, Nicolau, J, Mediavilla Garcia, J, Botella Serrano, M, Lecube, A, Arguelles, I, Sabán, J, Gómez Cerezo, F, Soto, A, Bellido, D, Sucunza Alfonso, N, Vendrell Ortega, J, Alvarez, L, Garcia Puig, J, Angustias Quesada, M, Contreras Gilbert, J, Almeida, Ca, Tinahones, Fj, Garcia Ortiz, L, Gómez Marcos MA, Aomar, I, Fernández Balsells, M, Distiller, L, Padayachee, T, Badat, A, Ebrahim, I, Naiker, P, Ranjith, N, Kelfkens, Y, Makan, H, Mogashoa, S, Fulat, M, Carim-Ganey, N, Coetzee, K, Govender, T, Nortje, H, Wilhase, A, Seedat, S, Gani, M, Ellis, G, Rheeder, P, Wing, J, Blignaut, S, Kaplan, H, Lottering, H, Pillai, P, Louw, C, Coetzer, T, Sheu, Whh, Chen, Jf, Yang, Cy, Tseng, St, Wang, Cy, Lai, Wt, Hung, Yj, Hsieh, Ic, Su, Sl, Pei, D, Benjasuratwong, Y, Purewal, T, Milward, A, Dimitropoulos, I, Kumar, S, Barber, T, Wiles, P, Dang, C, Adler, A, Philip, S, Bellary, S, Price, D, Oelbaum, R, Heller, S, Sathayapalan, T, Clark, J, Leese, G, Simpson, H, Kilvert, A, Dawson, A, Hall, T, Takhar, A, Bundy, C, Harvey, P, Maxwell, S, Asamoah-Owusu, Nj, Mcknight, J, Chatterjee, S, Calvert, J, Wright, A, Macrury, S, Macfarlane, D, Johnson, A, Litchfield, J, Field, B, Koval, O, Larin, O, Levchenko, O, Martynyuk, L, Maslyanko, V, Rudyk, I, Suprun, Y, Tseluyko, V, Botsyurko, V, Vatutin, M, Fushtey, I, Grishyna, O, Kuskalo, P, Panina, S, Pererva, L, Prysupa, L, Teliatnikova, Z, Sokolova, L, Vlasenko, M, Berenfus, V, Gyrina, O, Kopytsya, M, Vizir, V, Vayda, M, Shanik, M, Headapohl, D, Pahl, J, Aronoff, S, Bartkowiak, A Jr, Chang, A, Gaudiani, L, Kayne, D, Look, M, Patel, N, Moran, J, Stout, E, Tsao, J, Struble, R, Fishman, N, Rodbard, H, Lucas, K, Dugano-Daphnis, P, Merrick, B, Nadar, V, Severa, L, Sorli, C, Chang, M, Reed, J III, Grunberger, G, Bain, C, Bestermann, W Jr, Morawski, E, White, J, Azizad, M, Ukwade, P, Anekwe, A, Jimenez, A, Weiss, D, Green, S, Overcash, J, Eaton, C, Roseman, H, Soler, N, Mikell, F, Manos, P, Levinson, L, Claxton, E Jr, Weiss, R, Argoud, G, Bickel, L, Wilson, J, Short, B, Webster, B, Mcneill, R, Schnall, A, Force, R, Phillips, L, Bybee, K, Forker, A, Denham, D, Vonderhaar, T, Pullman, J, Kruger, D, Whitehouse, F, Wysham, C, Baron, M, Kravitz, A, Dushkin, H, Manning, Mb, Wine, A, Jaffrani, N, Chadha, C, Sperl-Hillen, J, Busch, R, Estevez, R, Robbins, D, Rassouli, N, Garvey, T, Oparil, S, Eckel, R, Mcdermott, M, Rasouli, N, Mcgill, J, Corder, C, Klonoff, D, Mills, R, Earl, J, Kessel, J, Cuddihy, R, Zimmerman, R, Dayamani, P, Oral, E, Zimering, M, Marks, J, Farnsworth, K, Sugimoto, D, Toth, P, Bhargava, A, Mcguire, D, Rohatgi, A, Davies, M, Peden, E, Wyne, K, Alfonso, L, Seyoum, B, Akpunonu, B, Feinglos, M, Reaven, P, Soule, J, Luttrell, L, Schactman, B, Canadas, R, Boggs, B, Abbott, L, Herring, C, Roberts, L, Hage-Korban, E, Schubart, U, Taylon, A, Tannenbaum, A, Kingsley, J, Lenhard, J, Biscoveanu, M, Cohen, J, Donovan, D, Laferrere, B, Thompson, N, Wade, T, Detweiler, R, Henson, B, White, A, Cavale, A, Ravi, C, Thomas, A, Goodman, H, Kalen, V, Fox, D, Dauber, I, Rizvi, S, Marcus, A, Mulford, M, Higgins, A, Chane, M, Bland, V, Osunkoya, A, Suresh, D, Khan, S, Anastasi, L, Bajaj, M, Eisen, H, Mudaliar, Sr, Powell, S, Carr, K, Tripathy, D, Azad, N, Wakefield, P, Acheatel, R, Bressler, P, Dean, J, El Shahawy, M, Gilbert, J, Haque, I, Humiston, D, Ison, R, Karounos, D, Lillestol, M, Ferrier, N, Labroo, A, Vo, A, D’Agostino, R, Dulin, M, Mcwilliams, A, Hargrove, J, Blumberg, E, Jackson, B, Staniloae, C, Salacata, A, Hidalgo, H Jr, Nicol, P, Digiovanna, M, Soufer, J, Mahabadi, V, Akinboboye, O, Arauz-Pacheco, C, Neutel, J, Dungan, K, Benson, M, Powell, T, Gandy, W, Rovner, S, Berk, M, Khan, A, Ledesma, G, Madu, I, Erickson, B, Radbill, M, Graves, M, Kaczmarek, G, Giep, S, Baldauf, C, Golden, G, Lesh, K, Davis, C, Godbole, N, Kirby, W, Razzaque, N, Bhatt, B, Wilson, M., Internal medicine, ACS - Diabetes & metabolism, and ACS - Microcirculation
- Subjects
Male ,medicine.medical_specialty ,EXSCEL Study Group ,Injections, Subcutaneous ,030209 endocrinology & metabolism ,Type 2 diabetes ,Kaplan-Meier Estimate ,030204 cardiovascular system & hematology ,Placebo ,Article ,Drug Administration Schedule ,GLP1-agonists ,03 medical and health sciences ,0302 clinical medicine ,Double-Blind Method ,Interquartile range ,Internal medicine ,Diabetes mellitus ,General & Internal Medicine ,medicine ,Humans ,Hypoglycemic Agents ,Least-Squares Analysis ,Aged ,Glycated Hemoglobin ,business.industry ,Venoms ,Semaglutide ,Incidence ,Type 2 diabetes, GLP1-agonists, exenatide, cardiovascular effects ,General Medicine ,11 Medical And Health Sciences ,Middle Aged ,medicine.disease ,Surgery ,Albiglutide ,Editorial ,Diabetes Mellitus, Type 2 ,Cardiovascular Diseases ,Exenatide ,Dulaglutide ,Female ,business ,Peptides ,cardiovascular effects ,medicine.drug - Abstract
BACKGROUND: The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. METHODS: We randomly assigned patients with type 2 diabetes, with or without previous cardiovascular disease, to receive subcutaneous injections of extended-release exenatide at a dose of 2 mg or matching placebo once weekly. The primary composite outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The coprimary hypotheses were that exenatide, administered once weekly, would be noninferior to placebo with respect to safety and superior to placebo with respect to efficacy. RESULTS: In all, 14,752 patients (of whom 10,782 [73.1%] had previous cardiovascular disease) were followed for a median of 3.2 years (interquartile range, 2.2 to 4.4). A primary composite outcome event occurred in 839 of 7356 patients (11.4%; 3.7 events per 100 person-years) in the exenatide group and in 905 of 7396 patients (12.2%; 4.0 events per 100 person-years) in the placebo group (hazard ratio, 0.91; 95% confidence interval [CI], 0.83 to 1.00), with the intention-to-treat analysis indicating that exenatide, administered once weekly, was noninferior to placebo with respect to safety (P
- Published
- 2017
- Full Text
- View/download PDF
3. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo
- Author
-
UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, Bentley-Lewis, R., Aguilar, D., Riddle, M.C., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H.C., Johnston, P., Køber, L.V., Lawson, F., Lewis, E.F., Maggioni, A.P., McMurray, J.J.V., Ping, L., Probstfield, J.L., Solomon, S.D., Tardif, J.-C., Wu, Y., Pfeffer, M.A., Barkoudah, E., Brahimi, A., Charytan, D., Finn, P., Flynn, A., Hartley, L.H., Henderson, G., Joseph, J., Odutayo, K., Rajesh, V., Vazir, A., Weinrauch, L., Del Prato, S., Petrie, J., Kaplan, A., Lieberman, P., Zuraw, B.L., O'Reilly, E., Patel, K., Allen, P., Scarpa, A., Schattner, M., Granger, C., Rouleau, J., DeMets, D., Chaturvedi, N., Raccah, D., Aizenberg, D., Alvarez, C., Alvarisqueta, A., Baccaro, C., Bartolacci, I., Bordonava, A., Bustamante Labarta, M., Caccavo, A., Calella, P., Cantero, M., Codutti, R., Commendatore, V., Costamagna, O., Cuello, J., Fernandez, A., Garcia Duran, R., Gomez Vilamajo, O., Gorban De Lapertosa, S., Grinfeld, D., Hermida, S., Lagrutta, M., Leon De La Fuente, R., Licheri, A., Luciardi, H., Mackinnon, I., Maffei, L., Marino, J., Montaña, O., Novaretto, L., Orio, S., Orlandini, A., Oviedo, A., Pérez Manghi, F., Patocchi, C., Ramos, H., Rolandi, F., Saa Zarandon, R., Saavedra, S.S., Schiavi, L., Schygiel, P., Trivi, M., Ulla, M., Urdiales, P., Vallejos, J., Vico, M., Waisman, F., Amerena, J., Paul, V., Sangla, K., Van Gaal, W., Yeap, B., Fasching, P., Pieber, T., Danilova, L., Mitkovskaya, N., Sudzhaeva, S., Mathieu, C., Pouleur, Anne-Catherine, Botelho, R.V., Cerqueira, M.J., Chacra, A., Dos Santos, F., Feitosa, G., Forti, A., Golbert, M., Halpern, A., Hissa, M., Lisboa, H., Moraes, J., Nery, M., Quadros, A., Raduan, R., Reis, G., Ribeiro Filho, F., Rollin, G., Rossi, P., Santos, E., Sgarbi, J., Souza, J., Souza, M.R., Delchev, A., Ivanov, V., Klyuchkova, N., Kyoleyan, M., Levterov, G., Lucheva, M., Raev, D., Shumkova, R., Tokmakova, M., Tzekova, M., Yordanov, V., Bailey, G., Bertrand, O., Bhargava, R., Burton, J., Campeau, J., Dumas, R., Filteau, P., Syan, G., Syan, R., Tsoukas, G., Warnica, J.W., Acuña, S., Araneda, G., Bunster, L., Cobos, L., Corbalán, R., Dussaillant, G., Eggers, G., Florenzano, F., Godoy, G., Huidobro, L.A., Lahsen, R., Lanas, F., Larenas, G., Manriquez, L., Medina, M., Palma, J.C., Perez, L., Potthoff, S., Raffo, C., Reyes, E., Saavedra, V., Sanhueza, P., Sepulveda, P., Solis, C.L., Soto, N., Torres, C., Westerberg, B., Yañez, M., Chen, L., Dong, Y., Du, J., Guo, X., Han, P., Hu, T., Jiang, B., Ke, Y., Li, Z., Lu, J., Ma, C., Peng, Y., Shi, Y., Su, G., Tang, B., Xu, B., Yang, J., Yang, Y., Accini, J.L., Arteaga, J.M., Botero, R., Castillo, G., Coronel, J., Cure, C., Garcia, H., Garcia, L., Gomez, C., Hernandez Triana, E., Hernandez, H., Lopez, M., Lopez, P., Manzur, F., Molina, D., Rodriguez, J., Sanchez Vallejo, G., Yupanqui, H., Bronnum-Schou, J., Kaiser Nielsen, P., Nielsen, H., Rønne, H., Rasmussen, S., Rungby, J., Skagen, K., Thomsen, K.K., Torp-Pedersen, C., Duarte-Vera, Y., Marmol Alvear, R., Peñaherrera-Patiño, C., Assaad, S., Shelbaya, S., Ambos, A., Jakovlev, U., Lubi, M., Märtsin, K., Rosenthal, S., Vides, H., Alanko, J., Korsoff, P., Koski, A.-M., Lahtela, J., Nelimarkka, L., Tuomilehto, J., Cariou, B., Catargi, B., Ducloux, R., Hadjadj, S., Kerlan, V., Malecot, J.-M., Petit, C., Rodier, M., Chumburidze, V., Glonti, S., Lominadze, Z., Todua, F., Contzen, C., Marck, C., Fischer, H., Hagenow, A., Himpel-Bönninghoff, A., Kihm, L., Killat, H., Kleinertz, K., Kosch, C., Kreutzmann, K., Lappo, M., Mertes, B., Piechatzek, R., Prohaska, M., Rinke, A., Schellenberg, D., Toursarkissian, N., Arango, J., Gonzalez, R., Granados, A., Herrera, M., Montenegro, P., Munoz, R., Rodriguez, E., Turcios, E., Villalobos, R., Wyss, F., Hatterjee, S., Chopda, M., Chopra, V., Deshpande, N., Dutta, R., Dwivedi, S., Gandhi, P., Gupta, S.K., Gupta, J.B., Gupta, S., Hiregouder, N., Jha, S., Joshi, A., Khan, N., Kumbla, M., Magdum, M., Murthy, K., Prabhu, M., Sahay, R., Sethuraman, S., Shah, N., Shamanna, P., Singh, K.S., Singh, P., Somasekharan, A., Sreenivasamurthy, L., Supe, P., Adawi, F., Atar, S., Cohen, O., Efrati, S., Karnieli, E., Klainman, E., Minuchin, O., Mosenzon, O., Stern, N., Turgeman, Y., Wainstein, J., Aimaretti, G., Berra, C., Ciardullo, A.V., Consoli, A., Cucinotta, D., Di Marco, S., Giorda, C., Giordano, C., Mannucci, E., Orsi, E., Piatti, P., Pontiroli, A., Ponzani, P., Pozzilli, P., Rivellese, A., Akahori, H., Eki, Y., Fujii, K., Hata, Y., Himeno, H., Hirayama, A., Kishimoto, I., Kobayashi, Y., Miyaoka, H., Niiya, T., Nishi, Y., Nozaki, A., Nunohiro, T., Saito, T., Satoh, Y., Takahashi, A., Takahashi, J., Takase, H., Takase, S., Tsuboko, Y., Tsujimoto, M., Tsujino, M., Tsuzuki, M., Watanabe, S., Yamada, T., Chung, W.J., Rim, S., Jang, H., Kim, U., Chung, C.H., Shin, S.-H., Kim, K., Kim, J., Rha, S., Lee, N.H., Kim, C.-J., Park, K.S., Amolina, I., Ducena, K., Helda, R., Konrade, I., Pirags, V., Sime, I., Sokolova, J., Kakariekiene, V., Kavaliauskiene, R., Petrulioniene, Z., Sakalyte, G., Urboniene, A., Zarankiene, R., Uribe, M., Garcia-Hernandez, P., Garza, J., Vazquez-Garcia, A., Gonzalez, J.G., Escalante, M., Zavala, A., Bayram, E., Hernandez-Muñuzuri, J., Ramos, Lopez, G.A., Lujan, J., Garcia-Soria, M., Velasco-Sanchez, R., Rodriguez, I., Jimenez, S., Galeana, C., Lara, S., Garcia-Castillo, A., Castro, M.G., Aguilar-Orozco, R., Lopez Rosas, E., Vidrio, M., Llamas, G., Stobschinski De Alba, C.A., Carranza-Madrigal, J., Cardosa-Torres, F., Cornel, J.H., Dekkers, P., Frederiks, J., Hermans, W., Lok, D., Meeder, J., Nierop, P., Cooper, J., Lappegård, K.T., Nedrebø, B.G., Castro, E., Gonzalez Castillo, B., Gonzalez, E., Nieto Ortega, R., Andrade, M., Calderon, J., Chavez, C., Correa Flores, R.M., Farfan, J., Lu, L., Luque, E., Manrique, H., Mogrovejo, W., Pariona-Javier, M., Pinto, M., Roldan, Y., Zubiate, C., Dans, A., Gomez, M.H., Panelo, A., Rey, N., Sulit, D.J., Sy, R.A., Timonera, M., Bednarski, J., Bijata-Bronisz, R., Bryniarski, L., Busz-Papiez, B., Czajkowska-Kaczmarek, E., Drzewiecka, A., Dulak, E., Gorska, M., Hamankiewicz, M., Janik, K., Kincel, K., Konieczny, M., Lubinski, A., Olszanecka-Glinianowicz, M., Ponikowski, P., Pulka, G., Rekosz, J., Skudlarski, D., Szymkowiak, K., Wilczewski, P., Bragança, N., Duarte, J., Monteiro, P., Rodrigues, E., Vinhas, M., Adina, P.-M., Avram, R.I., Cif, A., Creteanu, G., Dragomir, D., Ferariu, I.E., Iancu, A.-C., Istratoaie, O., Ivanica, G., Lichiardopol, R., Militaru, C., Minescu, B., Onaca, A., Pintilei, E., Podoleanu, C., Pop, L., Popa, B., Ranetti, A.E., Rosu, D., Tase, A., Tesloianu, D.N., Vinereanu, D., Ageev, F., Akhmedzhanov, N., Barbarash, O., Barbarich, V., Belousov, Y., Berns, S., Bokarev, I., Bolshakova, O., Boyarkin, M., Chumakova, G., Dmitry, P., Fitilev, S., Galyavich, A., Glezer, M., Ivanova, L., Kalashnikov, V., Kalashnikova, M., Karpov, Y., Khaisheva, L., Khalimov, Y., Kobalava, Z., Kosmachova, E., Kostenko, V., Koziolova, N., Kulibaba, E., Lesnov, V., Libov, I., Lyamina, N., Markov, V., Moiseev, V., Molchanova, O., Oleynikov, V., Orlikova, O., Panov, A., Rafalskiy, V., Rodionova, T., Samitin, V., Schokotov, V., Shilkina, N., Shogenov, Z., Shustov, S., Shvarts, Y., Sobolev, K., Stryuk, R., Suplotova, L., Viktorova, I., Vishnevsky, A., Vorokhobina, N., Yakusevich, V., Yakushin, S., Zadionchenko, V., Zalevskaya, A., Zalevsky, G., Zateyshchikova, A., Andjelic Jelic, M., Kocic, R., Komnenovic, S., Lalic, K., Lalic, N., Micic, D., Otasevic, P., Pesic, M., Seferovic, P., Stankovic, G., Arnold, S., Burgess, L., Coetzee, K., Dawood, S., Delport, E., Ebrahim, I., Ellis, G., Ismail, S., Kelbe, D., Naidoo, V., Ntsekhe, M., Sebastian, P.J., Siebert, M., Van Zyl, L., Venter, T., Lonso, E., Antorrena, I., Bodi, V., Botella, M., De La Fuente, J., Delgado, E., Duran Garcia, S., Elorza, J., Enciso, F., Gaztambide, S., Marin, F., Martin, V., Mauricio, D., Soto, A., Vida, M., Boberg, G., Jörneskog, G., Jendle, J., Mathiesen, U., Svensson, K.-A., Torstensson, I., Vasko, P., Moccetti, T., Chiang, C.-E., Chiu, Y.-W., Huang, T.-Y., Lu, C.-H., Pei, D., Shyu, K.-G., Ueng, K.-C., Wang, T.-D., Abid, M., Ben Abdallah, N., Haouala, H., Slimane, H., Zidi, B., Bascil Tutuncu, N., Camsari, A., Delibasi, T., Dinccag, N., Kultursay, H., Oto, A., Sahin, M., Saygili, F., Yigit, Z., Zorkun, C., Karpenko, O., Korpachev, V., Koval, O., Maslyanko, V., Perepelytsya, M., Pertseva, T., Petrosyan, O., Rudenko, L., Sychov, O., Synenko, V., Tseluyko, V., Zhuravleva, L., Al Mahmeed, W., Kaddaha, G.M., Andrews, R., Bain, S., Basu, A., Bhatnagar, D., Bickerton, A., Browne, D., Gibson, M., Hammond, P., Hanna, F., Issa, B., Jaap, A., Joseph, F., Jude, E., Kelly, C., Khan, A., Malik, R., Mukhopadhyay, B., O'Kane, M., Rayman, G., Robinson, A., Rooney, D., Sainsbury, C., Saravanan, P., Shakher, J., Singh, B., Turner, J., Whitelaw, D., Wilding, J., Wiles, P., Adenuga, B., Ahmad, Z., Akinboboye, O., Akright, L., Alappat, P., Alawad, M., Alfonso, T., Alimard, R., Alzohaili, O., Ariani, M., Arora, C., Azad, N., Azzam, S., Benjamin, S., Block, B., Borzadek, E., Breisblatt, W., Bright, T., Byrd, L., Chiou, C., Chochinov, R., Christensen, T., Christofides, E., Cohen, R., Dawood, G., De Souza, J., Dempsey, M., Eagerton, D., East, C., Elder, C., Fernando, R., Fogelfeld, L., Foucauld, J., French, W., Frohnauer, M., Gaffney, M., Gangopadhyay, S., Gogia, H., Gosmanov, A., Greenberg, C., Greenway, F., Hanna, E., Hargrove, J., Harris, A., Harris, B., Hart, T., Herrington, D., Hewitt, M., Howard, D., Izuora, K., Jetty, P., Kapoor, A., Kasper, J.F., Kelehan, S., Kelly, R., Kereiakes, D., Khaira, A., Khan, M., Khan, S., Korban, E., Kosiborod, M., Laguerre, J., Larocque, J., Latif, K., Lester, F., Levin, P., Levine, S., Li, C., Lovell, C., Lupovitch, S., Madu, I.-J., Mahabadi, V., Mahmood, A., Maragos, S., Mariash, C., Martin, P., Mathew, J., May, M., Mayfield, R., McCall, A., Mcdaniel, C., Mcgrew, F., Mckenzie, M., Mefford, I., Mehta, A., Mikdadi, G., Mikhail, M., Monchamp, T., Moore, C., Moran, M., Morrar, N., Mosley, J., Mulford, M., Murray, J., Nakhle, S., Nallasivan, M., Odio, A., Oh, C., Olelewe, S., Palchick, B., Paliwal, Y., Papademetriou, V., Parikh, N., Patel, S., Phillips, L., Pitts, T., Prieto, F., Puttnam, R., Quyyumi, A., Randhawa, P., Rendell, M., Rhie, F., Roberts, J., Robinson, J., Robinson, M., Rubino, J., Ryan, E., Saathoff, S., Sachmechi, I., Saifi, A., Salacata, A., Sanders, R., Sanson, J., Savin, V., Schabauer, A., Schmedtje, J., Schwartz, A., Scott, C., Selagamsetty, M., Shannon, M., Shaw, S., Singal, D., Sjoberg, R., Smith, K., Sofley, C., Sonn, A., Sorof, S., Soroka, E., Spellman, C.W., Steinhoff, J., Suresh, D., Tahir, M., Tanenberg, R., Thawani, H., Thomson, S., Thrasher, J., Trachtenbarg, D., Trotta, M., Tuan, W., Twahirwa, M., Umpierrez, G., Vaid, B., Vance, C., Wang, T., Warner, A., Watson, H., Weber, S., Webster, B., Weindorff, K., Welch, M., Welker, J., White, A., White, L., Williams, M., Wu, W.-C., Wynne, A., Yocono, M., Yuen, K., UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, Bentley-Lewis, R., Aguilar, D., Riddle, M.C., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H.C., Johnston, P., Køber, L.V., Lawson, F., Lewis, E.F., Maggioni, A.P., McMurray, J.J.V., Ping, L., Probstfield, J.L., Solomon, S.D., Tardif, J.-C., Wu, Y., Pfeffer, M.A., Barkoudah, E., Brahimi, A., Charytan, D., Finn, P., Flynn, A., Hartley, L.H., Henderson, G., Joseph, J., Odutayo, K., Rajesh, V., Vazir, A., Weinrauch, L., Del Prato, S., Petrie, J., Kaplan, A., Lieberman, P., Zuraw, B.L., O'Reilly, E., Patel, K., Allen, P., Scarpa, A., Schattner, M., Granger, C., Rouleau, J., DeMets, D., Chaturvedi, N., Raccah, D., Aizenberg, D., Alvarez, C., Alvarisqueta, A., Baccaro, C., Bartolacci, I., Bordonava, A., Bustamante Labarta, M., Caccavo, A., Calella, P., Cantero, M., Codutti, R., Commendatore, V., Costamagna, O., Cuello, J., Fernandez, A., Garcia Duran, R., Gomez Vilamajo, O., Gorban De Lapertosa, S., Grinfeld, D., Hermida, S., Lagrutta, M., Leon De La Fuente, R., Licheri, A., Luciardi, H., Mackinnon, I., Maffei, L., Marino, J., Montaña, O., Novaretto, L., Orio, S., Orlandini, A., Oviedo, A., Pérez Manghi, F., Patocchi, C., Ramos, H., Rolandi, F., Saa Zarandon, R., Saavedra, S.S., Schiavi, L., Schygiel, P., Trivi, M., Ulla, M., Urdiales, P., Vallejos, J., Vico, M., Waisman, F., Amerena, J., Paul, V., Sangla, K., Van Gaal, W., Yeap, B., Fasching, P., Pieber, T., Danilova, L., Mitkovskaya, N., Sudzhaeva, S., Mathieu, C., Pouleur, Anne-Catherine, Botelho, R.V., Cerqueira, M.J., Chacra, A., Dos Santos, F., Feitosa, G., Forti, A., Golbert, M., Halpern, A., Hissa, M., Lisboa, H., Moraes, J., Nery, M., Quadros, A., Raduan, R., Reis, G., Ribeiro Filho, F., Rollin, G., Rossi, P., Santos, E., Sgarbi, J., Souza, J., Souza, M.R., Delchev, A., Ivanov, V., Klyuchkova, N., Kyoleyan, M., Levterov, G., Lucheva, M., Raev, D., Shumkova, R., Tokmakova, M., Tzekova, M., Yordanov, V., Bailey, G., Bertrand, O., Bhargava, R., Burton, J., Campeau, J., Dumas, R., Filteau, P., Syan, G., Syan, R., Tsoukas, G., Warnica, J.W., Acuña, S., Araneda, G., Bunster, L., Cobos, L., Corbalán, R., Dussaillant, G., Eggers, G., Florenzano, F., Godoy, G., Huidobro, L.A., Lahsen, R., Lanas, F., Larenas, G., Manriquez, L., Medina, M., Palma, J.C., Perez, L., Potthoff, S., Raffo, C., Reyes, E., Saavedra, V., Sanhueza, P., Sepulveda, P., Solis, C.L., Soto, N., Torres, C., Westerberg, B., Yañez, M., Chen, L., Dong, Y., Du, J., Guo, X., Han, P., Hu, T., Jiang, B., Ke, Y., Li, Z., Lu, J., Ma, C., Peng, Y., Shi, Y., Su, G., Tang, B., Xu, B., Yang, J., Yang, Y., Accini, J.L., Arteaga, J.M., Botero, R., Castillo, G., Coronel, J., Cure, C., Garcia, H., Garcia, L., Gomez, C., Hernandez Triana, E., Hernandez, H., Lopez, M., Lopez, P., Manzur, F., Molina, D., Rodriguez, J., Sanchez Vallejo, G., Yupanqui, H., Bronnum-Schou, J., Kaiser Nielsen, P., Nielsen, H., Rønne, H., Rasmussen, S., Rungby, J., Skagen, K., Thomsen, K.K., Torp-Pedersen, C., Duarte-Vera, Y., Marmol Alvear, R., Peñaherrera-Patiño, C., Assaad, S., Shelbaya, S., Ambos, A., Jakovlev, U., Lubi, M., Märtsin, K., Rosenthal, S., Vides, H., Alanko, J., Korsoff, P., Koski, A.-M., Lahtela, J., Nelimarkka, L., Tuomilehto, J., Cariou, B., Catargi, B., Ducloux, R., Hadjadj, S., Kerlan, V., Malecot, J.-M., Petit, C., Rodier, M., Chumburidze, V., Glonti, S., Lominadze, Z., Todua, F., Contzen, C., Marck, C., Fischer, H., Hagenow, A., Himpel-Bönninghoff, A., Kihm, L., Killat, H., Kleinertz, K., Kosch, C., Kreutzmann, K., Lappo, M., Mertes, B., Piechatzek, R., Prohaska, M., Rinke, A., Schellenberg, D., Toursarkissian, N., Arango, J., Gonzalez, R., Granados, A., Herrera, M., Montenegro, P., Munoz, R., Rodriguez, E., Turcios, E., Villalobos, R., Wyss, F., Hatterjee, S., Chopda, M., Chopra, V., Deshpande, N., Dutta, R., Dwivedi, S., Gandhi, P., Gupta, S.K., Gupta, J.B., Gupta, S., Hiregouder, N., Jha, S., Joshi, A., Khan, N., Kumbla, M., Magdum, M., Murthy, K., Prabhu, M., Sahay, R., Sethuraman, S., Shah, N., Shamanna, P., Singh, K.S., Singh, P., Somasekharan, A., Sreenivasamurthy, L., Supe, P., Adawi, F., Atar, S., Cohen, O., Efrati, S., Karnieli, E., Klainman, E., Minuchin, O., Mosenzon, O., Stern, N., Turgeman, Y., Wainstein, J., Aimaretti, G., Berra, C., Ciardullo, A.V., Consoli, A., Cucinotta, D., Di Marco, S., Giorda, C., Giordano, C., Mannucci, E., Orsi, E., Piatti, P., Pontiroli, A., Ponzani, P., Pozzilli, P., Rivellese, A., Akahori, H., Eki, Y., Fujii, K., Hata, Y., Himeno, H., Hirayama, A., Kishimoto, I., Kobayashi, Y., Miyaoka, H., Niiya, T., Nishi, Y., Nozaki, A., Nunohiro, T., Saito, T., Satoh, Y., Takahashi, A., Takahashi, J., Takase, H., Takase, S., Tsuboko, Y., Tsujimoto, M., Tsujino, M., Tsuzuki, M., Watanabe, S., Yamada, T., Chung, W.J., Rim, S., Jang, H., Kim, U., Chung, C.H., Shin, S.-H., Kim, K., Kim, J., Rha, S., Lee, N.H., Kim, C.-J., Park, K.S., Amolina, I., Ducena, K., Helda, R., Konrade, I., Pirags, V., Sime, I., Sokolova, J., Kakariekiene, V., Kavaliauskiene, R., Petrulioniene, Z., Sakalyte, G., Urboniene, A., Zarankiene, R., Uribe, M., Garcia-Hernandez, P., Garza, J., Vazquez-Garcia, A., Gonzalez, J.G., Escalante, M., Zavala, A., Bayram, E., Hernandez-Muñuzuri, J., Ramos, Lopez, G.A., Lujan, J., Garcia-Soria, M., Velasco-Sanchez, R., Rodriguez, I., Jimenez, S., Galeana, C., Lara, S., Garcia-Castillo, A., Castro, M.G., Aguilar-Orozco, R., Lopez Rosas, E., Vidrio, M., Llamas, G., Stobschinski De Alba, C.A., Carranza-Madrigal, J., Cardosa-Torres, F., Cornel, J.H., Dekkers, P., Frederiks, J., Hermans, W., Lok, D., Meeder, J., Nierop, P., Cooper, J., Lappegård, K.T., Nedrebø, B.G., Castro, E., Gonzalez Castillo, B., Gonzalez, E., Nieto Ortega, R., Andrade, M., Calderon, J., Chavez, C., Correa Flores, R.M., Farfan, J., Lu, L., Luque, E., Manrique, H., Mogrovejo, W., Pariona-Javier, M., Pinto, M., Roldan, Y., Zubiate, C., Dans, A., Gomez, M.H., Panelo, A., Rey, N., Sulit, D.J., Sy, R.A., Timonera, M., Bednarski, J., Bijata-Bronisz, R., Bryniarski, L., Busz-Papiez, B., Czajkowska-Kaczmarek, E., Drzewiecka, A., Dulak, E., Gorska, M., Hamankiewicz, M., Janik, K., Kincel, K., Konieczny, M., Lubinski, A., Olszanecka-Glinianowicz, M., Ponikowski, P., Pulka, G., Rekosz, J., Skudlarski, D., Szymkowiak, K., Wilczewski, P., Bragança, N., Duarte, J., Monteiro, P., Rodrigues, E., Vinhas, M., Adina, P.-M., Avram, R.I., Cif, A., Creteanu, G., Dragomir, D., Ferariu, I.E., Iancu, A.-C., Istratoaie, O., Ivanica, G., Lichiardopol, R., Militaru, C., Minescu, B., Onaca, A., Pintilei, E., Podoleanu, C., Pop, L., Popa, B., Ranetti, A.E., Rosu, D., Tase, A., Tesloianu, D.N., Vinereanu, D., Ageev, F., Akhmedzhanov, N., Barbarash, O., Barbarich, V., Belousov, Y., Berns, S., Bokarev, I., Bolshakova, O., Boyarkin, M., Chumakova, G., Dmitry, P., Fitilev, S., Galyavich, A., Glezer, M., Ivanova, L., Kalashnikov, V., Kalashnikova, M., Karpov, Y., Khaisheva, L., Khalimov, Y., Kobalava, Z., Kosmachova, E., Kostenko, V., Koziolova, N., Kulibaba, E., Lesnov, V., Libov, I., Lyamina, N., Markov, V., Moiseev, V., Molchanova, O., Oleynikov, V., Orlikova, O., Panov, A., Rafalskiy, V., Rodionova, T., Samitin, V., Schokotov, V., Shilkina, N., Shogenov, Z., Shustov, S., Shvarts, Y., Sobolev, K., Stryuk, R., Suplotova, L., Viktorova, I., Vishnevsky, A., Vorokhobina, N., Yakusevich, V., Yakushin, S., Zadionchenko, V., Zalevskaya, A., Zalevsky, G., Zateyshchikova, A., Andjelic Jelic, M., Kocic, R., Komnenovic, S., Lalic, K., Lalic, N., Micic, D., Otasevic, P., Pesic, M., Seferovic, P., Stankovic, G., Arnold, S., Burgess, L., Coetzee, K., Dawood, S., Delport, E., Ebrahim, I., Ellis, G., Ismail, S., Kelbe, D., Naidoo, V., Ntsekhe, M., Sebastian, P.J., Siebert, M., Van Zyl, L., Venter, T., Lonso, E., Antorrena, I., Bodi, V., Botella, M., De La Fuente, J., Delgado, E., Duran Garcia, S., Elorza, J., Enciso, F., Gaztambide, S., Marin, F., Martin, V., Mauricio, D., Soto, A., Vida, M., Boberg, G., Jörneskog, G., Jendle, J., Mathiesen, U., Svensson, K.-A., Torstensson, I., Vasko, P., Moccetti, T., Chiang, C.-E., Chiu, Y.-W., Huang, T.-Y., Lu, C.-H., Pei, D., Shyu, K.-G., Ueng, K.-C., Wang, T.-D., Abid, M., Ben Abdallah, N., Haouala, H., Slimane, H., Zidi, B., Bascil Tutuncu, N., Camsari, A., Delibasi, T., Dinccag, N., Kultursay, H., Oto, A., Sahin, M., Saygili, F., Yigit, Z., Zorkun, C., Karpenko, O., Korpachev, V., Koval, O., Maslyanko, V., Perepelytsya, M., Pertseva, T., Petrosyan, O., Rudenko, L., Sychov, O., Synenko, V., Tseluyko, V., Zhuravleva, L., Al Mahmeed, W., Kaddaha, G.M., Andrews, R., Bain, S., Basu, A., Bhatnagar, D., Bickerton, A., Browne, D., Gibson, M., Hammond, P., Hanna, F., Issa, B., Jaap, A., Joseph, F., Jude, E., Kelly, C., Khan, A., Malik, R., Mukhopadhyay, B., O'Kane, M., Rayman, G., Robinson, A., Rooney, D., Sainsbury, C., Saravanan, P., Shakher, J., Singh, B., Turner, J., Whitelaw, D., Wilding, J., Wiles, P., Adenuga, B., Ahmad, Z., Akinboboye, O., Akright, L., Alappat, P., Alawad, M., Alfonso, T., Alimard, R., Alzohaili, O., Ariani, M., Arora, C., Azad, N., Azzam, S., Benjamin, S., Block, B., Borzadek, E., Breisblatt, W., Bright, T., Byrd, L., Chiou, C., Chochinov, R., Christensen, T., Christofides, E., Cohen, R., Dawood, G., De Souza, J., Dempsey, M., Eagerton, D., East, C., Elder, C., Fernando, R., Fogelfeld, L., Foucauld, J., French, W., Frohnauer, M., Gaffney, M., Gangopadhyay, S., Gogia, H., Gosmanov, A., Greenberg, C., Greenway, F., Hanna, E., Hargrove, J., Harris, A., Harris, B., Hart, T., Herrington, D., Hewitt, M., Howard, D., Izuora, K., Jetty, P., Kapoor, A., Kasper, J.F., Kelehan, S., Kelly, R., Kereiakes, D., Khaira, A., Khan, M., Khan, S., Korban, E., Kosiborod, M., Laguerre, J., Larocque, J., Latif, K., Lester, F., Levin, P., Levine, S., Li, C., Lovell, C., Lupovitch, S., Madu, I.-J., Mahabadi, V., Mahmood, A., Maragos, S., Mariash, C., Martin, P., Mathew, J., May, M., Mayfield, R., McCall, A., Mcdaniel, C., Mcgrew, F., Mckenzie, M., Mefford, I., Mehta, A., Mikdadi, G., Mikhail, M., Monchamp, T., Moore, C., Moran, M., Morrar, N., Mosley, J., Mulford, M., Murray, J., Nakhle, S., Nallasivan, M., Odio, A., Oh, C., Olelewe, S., Palchick, B., Paliwal, Y., Papademetriou, V., Parikh, N., Patel, S., Phillips, L., Pitts, T., Prieto, F., Puttnam, R., Quyyumi, A., Randhawa, P., Rendell, M., Rhie, F., Roberts, J., Robinson, J., Robinson, M., Rubino, J., Ryan, E., Saathoff, S., Sachmechi, I., Saifi, A., Salacata, A., Sanders, R., Sanson, J., Savin, V., Schabauer, A., Schmedtje, J., Schwartz, A., Scott, C., Selagamsetty, M., Shannon, M., Shaw, S., Singal, D., Sjoberg, R., Smith, K., Sofley, C., Sonn, A., Sorof, S., Soroka, E., Spellman, C.W., Steinhoff, J., Suresh, D., Tahir, M., Tanenberg, R., Thawani, H., Thomson, S., Thrasher, J., Trachtenbarg, D., Trotta, M., Tuan, W., Twahirwa, M., Umpierrez, G., Vaid, B., Vance, C., Wang, T., Warner, A., Watson, H., Weber, S., Webster, B., Weindorff, K., Welch, M., Welker, J., White, A., White, L., Williams, M., Wu, W.-C., Wynne, A., Yocono, M., and Yuen, K.
- Abstract
Background: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagonlike peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated. Methods: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallelgroup, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population at high CV risk. The primary efficacy end point is a composite of time to CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. Data are systematically collected for safety outcomes, including hypoglycemia, pancreatitis, and malignancy. Results: Enrollment began in July 2010 and ended in August 2013; 6,068 patients from 49 countries were randomized. Of these, 69% are men and 75% are white; at baseline, the mean ± SD age was 60.3 ± 9.7 years, body mass index was 30.2 ± 5.7 kg/m2, and duration of T2DM was 9.3±8.2 years. The qualifying ACS wasamyocardial infarctionin83% and unstableangina in 17%. The study will continue until the positive adjudication of the protocol-specified number of primary CV events. Conclusion: ELIXA will be the first trial to report the safety and efficacy of a glucagon-like peptide 1 receptor agonist in people with T2DM and high CV event risk. © 2015 Elsevier Inc. All rights reserved.
- Published
- 2015
4. Intravenous injection of human umbilical cord matrix stem cell (Wharton jelly stem cell) provides functional recovery in a rat model of traumatic brain injury
- Author
-
Marzban, M., Bakhtiary, M., Mehdizadeh, M., Mohammad Taghi Joghataei, Khoei, S., Mahabadi, V. P., Hashemian, S. J., Tondar, M., Laribi, B., Ebrahimi, A., and Abhari, B.
- Subjects
Injection ,Stem Cell ,lcsh:R ,lcsh:Medicine ,lcsh:Q ,Brain Injury ,lcsh:Science - Abstract
Objective: This study was designed to examine the effects of human umbilical cord matrixstem cell (hUCMSC) administration in rats for 6 weeks after traumatic brain injury (TBI).Materials and Methods: Adult male Wistar rats (n = 30) were injured with controlled corticalimpact device and divided into three groups. The treatment group (n = 10) was injectedwith 2 × 106 hUCMSC intravenously, the vehicle group (n=10) received phosphate bufferedsaline (PBS) whereas the control group (n = 10) receive nothing. All injections wereperformed one day after injury into the tail veins of the rats. All cells were labelled withBrdu before injection. Evaluation of the neurological function of the rats was performedbefore and after injury using Neurological Severity Scores (NSS). The rats were sacrificed6 weeks after TBI and brain sections were stained using Brdu immunohistochemistry.Results: Statistically significant improvement in functional outcome was observed in thetreatment group compared with the control group (p < 0.01). This benefit was visible 1 weekafter TBI and persisted for six weeks (end of trial). Histological analysis showed that hUCMSCwere present in the lesion boundary zone at 6 weeks in all cell injected animals.Conclusion: Rats injected with hUCMSC after TBI survive for at least six weeks and showfunctional improvemnt.
5. Anti-Leishmanial Effects of a Novel Biocompatible Non-Invasive Nanofibers Containing Royal Jelly and Propolis against Iranian Strain of Leishmania major (MRHO/IR/75/ER): an In-Vitro Study.
- Author
-
Mahmoudi M, Mehravi B, Shabani M, Hadighi R, Badirzadeh A, Dehdast A, Chizari-Fard G, Pirhajati-Mahabadi V, Akbari S, Tabatabaie F, and Mohebali M
- Abstract
Background: Current medications especially the pentavalent antimonial compounds have been used as the first line treatment of cutaneous leishmaniasis (CL), but they have limitations due to serious side effects such as drug resistance, cardio and nephrotoxicity, and high costs. Hence, the demand to find more usable drugs is evident. Synthesis and development of natural, effective, biocompatible, and harmless compounds against Leishmania major is the principal priority of this study., Methods: By electrospinning method, a new type of nanofiber were synthesized from royal jelly and propolis with different ratios. Nanofibers were characterized by Scanning Electron Microscope (SEM), Transmission Electron Microscopy (TEM), Thermogravimetric Analysis (TGA), Contact angle, and Fourier-transform infrared spectroscopy (FTIR). The Half-maximal inhibitory concentration (IC
50 ), Half-maximal effective concentration (EC50 ) and the 50% cytotoxic concentration (CC50 ) for different concentrations of nanofibers were determined using quantitative calorimetric methods. Inductively coupled plasma-optical emission spectrometry (ICP-OES) and flow cytometry were performed as complementary tests., Results: The results showed that the proposed formulas provide a new achievement that, despite the significant killing activity on L. major , has negligible cytotoxicity on the host cells. Royal jelly nanofibers have significantly shown the best 72 hours results (IC50 = 35 μg/ml and EC50 =16.4 μg/ml) and the least cytotoxicity., Conclusion: This study presents a great challenge to introduce a new low-cost treatment method for CL, accelerate wound healing, and reduce scarring with minimal side effects and biocompatible materials. Royal jelly and propolis nanofibers significantly inhibit the growth of L. major in-vitro ., (Copyright © 2023 The Authors. Published by Tehran University of Medical Sciences.)- Published
- 2023
- Full Text
- View/download PDF
6. Enhanced anti-tumor activity of transferrin/folate dual-targeting magnetic nanoparticles using chemo-thermo therapy on retinoblastoma cancer cells Y79.
- Author
-
Sadri E, Khoee S, Moayeri S, Haji Ali B, Pirhajati Mahabadi V, Shirvalilou S, and Khoei S
- Subjects
- Child, Humans, Reactive Oxygen Species, Folic Acid, Transferrin, Vincristine pharmacology, Vincristine therapeutic use, Cell Line, Tumor, Retinoblastoma drug therapy, Magnetite Nanoparticles, Hyperthermia, Induced, Retinal Neoplasms drug therapy, Nanoparticles
- Abstract
Malignant neoplasms are one of the main causes of death, especially in children, on a global scale, despite strenuous efforts made at advancing both diagnostic and therapeutic modalities. In this regard, a new nanocarrier Vincristine (VCR)-loaded Pluronic f127 polymer-coated magnetic nanoparticles conjugated with folic acid and transferrin (PMNP-VCR-FA-TF) were synthesized and characterized by various methods. The cytotoxicity of these nanoparticles was evaluated in vitro and ex vivo conditions. The in vitro anti-tumor effect of the nanoparticles was evaluated by colony formation assay (CFA) and reactive oxygen species (ROS) in Y79 cell line. The results showed that nanoparticles with two ligands conferred greater toxicity toward Y79 cancer cells than ARPE19 normal cells. Under an alternating magnetic field (AMF), these nanoparticles demonstrated a high specific absorption rate. The CFA and ROS results indicated that the AMF in combination with PMNP-VCR-FA-TF conferred the highest cytotoxicity toward Y79 cells compared with other groups (P < 0.05). PMNP-VCR-FA-TF could play an important role in converting externally applied radiofrequency energy into heat in cancer cells. The present study confirmed that dual targeting chemo-hyperthermia using PMNP-VCR-FA-TF was significantly more effective than hyperthermia or chemotherapy alone, providing a promising platform for precision drug delivery as an essential component in the chemotherapy of retinoblastoma., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
7. Antifungal activity of green-synthesized curcumin-coated silver nanoparticles alone and in combination with fluconazole and itraconazole against Candida and Aspergillus species.
- Author
-
Amini SM, I Getso M, Farahyar S, Khodavaisy S, Roudbary M, Pirhajati Mahabadi V, and Mahmoudi S
- Abstract
Background and Purpose: Regarding the wide-spectrum antimicrobial effects of curcumin and silver, this study aimed to evaluate the antifungal activity of green-synthesized curcumin-coated silver nanoparticles (Cur-Ag NPs) against a set of Candida and Aspergillus species., Materials and Methods: Cur-Ag NPs were synthesized by mixing 200 µL of curcumin solution (40 mM) and 15 mL of deionized water. The mixture was stirred for 3-5 min, followed by the addition of 2.5 mL of silver nitrate solution (2.5 mM). The resulting solution was incubated for 3 days. Antifungal susceptibility of 30 fungal isolates of Aspergillus and Candida to fluconazole and itraconazole, as well as the activity of Cur-Ag NPs against the isolates, were determined, both alone and in combination, using broth microdilution according to the Clinical and Laboratory Standards Institute guidelines., Results: Cur-Ag NPs demonstrated promising antifungal activity, particularly against Candida species. The geometric mean value of the minimum inhibitory concentration of Cur-Ag NPs was significantly lower than that of fluconazole for all the studied fungi. Similarly, it was lower than those of itraconazole in C. albicans and A. fumigatus . The minimum fungicidal concentrations of Cur-Ag NPs were markedly better than those of fluconazole but still inferior to those of itraconazole., Conclusion: Cur-Ag NPs demonstrated indisputable antifungal activity and great potential that can be harnessed to combat fungal infections, particularly those caused by azole-resistant strains of Aspergillus and Candida ., Competing Interests: Nothing to declare., (Copyright: © 2021, Published by Mazandaran University of Medical Sciences on behalf of Iranian Society of Medical Mycology and Invasive Fungi Research Center.)
- Published
- 2023
- Full Text
- View/download PDF
8. Effect of PLGA Nanoparticle-Mediated Delivery of miRNA 503 on The Apoptosis of Ovarian Endometriosis Cells.
- Author
-
Chaichian S, Mehdizadeh Kashi A, Tehermanesh K, Pirhajati Mahabadi V, Minaeian S, and Eslahi N
- Abstract
Objective: One of the challenges in gene therapy is the transfer of the gene to the target cell. MicroRNAs (miRNAs) regulate gene expression after transcription by binding directly to the messenger and play a vital role in cell behaviors and the pathogenesis of some diseases. This study was aimed at developing poly (lactic-co-glycolic acid) (PLGA)- based nanoparticles (NPs) for gene delivery to endometriotic cyst stromal cells (ECSCs)., Materials and Methods: In this experimental study, endometriosis cells were isolated from women with severe endometriosis (DIE) and digested by the enzymatic method (40 μg/ml DNAase I and 300 μg/ml collagenase type 3). PLGA-based NPs were synthesized and characterized. The size of sole PLGA NPs and PLGA/miRNA were 60 ± 4 nm and 70 ± 5.1 nm respectively. Poly lactic-co-glycolic-based NPs were used as vector carriers for miRNA 503 transfection in endometriosis cells. The cells were divided into the five groups of control and four doses (25, 50, 75, and 100 μm) of miRNA 503/PLGA at 12, 24, 48, and 72 hours. Viability and apoptosis were evaluated by the MTT assay and Annexin Kits. Data were analyzed by one-way analysis of variance., Results: The results show that the size of PLGA/miRNA complex with dynamic light scattering (DLS) was 70 ± 5.1 nm and zeta potential values of the PLGA/PEI/miRNA complexes were 27.9 mV. Based on the MTT assay results, the optimal dose of miRNA 503/PLGA was 75 μm, at which the viability of ECSCs was 52.6% ± 1.2 (P≤0.001), and the optimal time was 48 hours. The apoptotic rates of ECSCs treated with PLGA/miRNA503 (34.75 ± 4.9%) were significantly higher than those of ECSCs treated with PLGA alone (3.35 ± 2.58%, P≤0.01)., Conclusion: Cell death increased with increasing the concentration of miRNA; thus, it can be suggested as a treatment for endometriosis.
- Published
- 2022
- Full Text
- View/download PDF
9. Anti-biofilm Activity of a Lytic Phage Against Vancomycin-Resistant Enterococcus faecalis .
- Author
-
Goodarzi F, Hallajzadeh M, Sholeh M, Talebi M, Pirhajati Mahabadi V, and Amirmozafari N
- Abstract
Background & Objective: This study aims to isolate a lytic bacteriophage against planktonic Enterococcus faecalis V583 culture and evaluate its ability to disrupt and inhibit biofilm., Methods: An anti- E. faecalis phage was isolated from sewage and visualized by electron microscopy, the vB_EfsS_V583 (V583) host range was determined by spot test on 13 E. faecalis clinical strains. Inhibition and degradation experiments were designed to investigate the effect of phage on biofilm. In the inhibition and degradation assay, biofilms were formed in the presence and absence of phage, respectively. Finally, crystal violet method tested the effect of phage on biofilm., Results: Phage V583 belongs to the Siphoviridae family and can infect all E. faecalis strains. Antibacterial activity has been shown to degrade and inhibit biofilm produced by V583. The study results showed that phage v583 is more efficient in biofilm inhibition than biofilm degradation. In both assays, phage-treated wells' absorption is less than untreated wells. These results were confirmed by Colony-forming unit reduction in the treated biofilm., Conclusion: The anti-biofilm activity showed that phage therapy using phage V583 might be an alternative tool to remove E. faecalis biofilms., Competing Interests: The authors declared no conflict of interests.
- Published
- 2022
- Full Text
- View/download PDF
10. Metabotropic glutamate receptor: A new possible therapeutic target for cochlear synaptopathy.
- Author
-
Mahdi P, Pourbakht A, Karimi Yazdi A, Rabbani Anari M, Pirhajati Mahabadi V, and Kamali M
- Abstract
Objectives: Cochlear synaptopathy is a common cause of auditory disorders in which glutamate over-activation occurs. Modulating glutamatergic pathways has been proposed to down-regulate post-synaptic excitation., Materials and Methods: 12-guinea pigs as sham and test groups were exposed to a 4-kHz noise at 104 dB SPL, for 2 hr. Pre-exposure intra-tympanic injection with LY354740 and normal saline 9% was applied in the test and sham groups. The amplitude growth of ABR-wave-I and wave-III latency shift with noise were considered in pre- and post-exposure times. The synapses were observed by transmission electron-microscopy., Results: ABR thresholds recovered 1-week post-exposure in both groups. The reduction of wave-I amplitude at 4, 6, and 8 kHz were statistically different between pre- and 1- day post-exposure and recovered mostly in the sham group. The amount of latency shift in masked ABR was different between pre- and all post-exposure, and the response could not be detected at higher than 50 dB SL noise. However, the response detectability increased to 60 dB SL noise, and the significance of differences between pre- and post-exposure persisted only at the high level of noise in the test group. In electron-microscopy of sham samples, the size of the ribbon was larger, spherical with an irregularity, and hollow. The post-synaptic density was thicker and missed its flat orientation., Conclusion: The higher slope of the ABR-wave I amplitude, the more tolerance of noise in masked ABR, concomitant with the histological finding that revealed less synaptic damage, confirmed the therapeutic effect of LY354740 in cochlear synaptopathy., Competing Interests: The authors declare that no conflict of interest exists.
- Published
- 2022
- Full Text
- View/download PDF
11. DNA methyltransferase inhibitor 5-azacytidine in high dose promotes ultrastructural maturation of cardiomyocyte.
- Author
-
Saheli M, Pirhajati Mahabadi V, Mesbah-Namin SA, Seifalian A, and Bagheri-Hosseinabadi Z
- Abstract
Background: The adult human heart muscle cells, cardiomyocytes are not capable of regenerate after injury. Stem cells are a powerful means for future regenerative medicine because of their capacity for self-renewal and multipotency. Several studies have reported the cardiogenic potential in human adipose tissue-derived stem cells (ADSCs) differentiation, but there is still no efficient protocol for the induction of cardiac differentiation by 5-azacytidine (5-Aza). The present study involves characterization and mainly, the ultrastructure of ADSCs derived cardiomyocyte-like cells., Methods: The cultured ADSCs were treated with 50 µM 5-Aza for 24 hours, followed by a 10-week extension. At different time points, cardiomyocyte-like cells were assessed by qRT-PCR and were evaluated by transmission electron microscopy at 10
th week., Results: The expression of cardiac-specific markers entailing cardiac troponin I (cTnI), connexin 43, myosin light chain-2v (Mlc-2v), increased over 10 weeks and the highest expression was at 10th week. The expression of the β-myosin heavy chain (β-MHC) increased significantly over 5 weeks and then decreased. At the ultrastructural level myofibrils, transverse tubules (T-tubules), sarcoplasmic reticular membrane, and intercalated discs were present., Conclusions: These data suggest that treatment with 5-Aza in high dose could promote differentiation of ADSCs into cardiomyocyte-like cells. These differentiated cells could be used for regeneration of damaged cardiomyocytes with the 3D scaffold for delivery of the cells., Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/sci-2020-007). The authors have no conflicts of interest to declare., (2020 Stem Cell Investigation. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
12. Anti-inflammatory and anti-apoptotic effects of hyperbaric oxygen preconditioning in a rat model of cisplatin-induced peripheral neuropathy.
- Author
-
Khademi E, Pirhajati Mahabadi V, Ahmadvand H, Akbari E, and Khalatbary AR
- Abstract
Objectives: Cisplatin-induced peripheral neuropathy is a debilitating side effect in patients receiving this drug. Recent studies suggest hyperbaric oxygen (HBO) therapy as a new treatment approach for models of neural injury. The aim of the current study was to determine the protective effects of HBO preconditioning against peripheral neuropathy induced by Cisplatin (CDDP)., Materials and Methods: The present study was conducted on 4 groups of rats: Sham group; HBO group (60 min/d); Control group (CDDP 2 mg/kg/d); Precondition group (HBO+CDDP). Mechanical threshold testing was weekly carried out using von Frey filament. Sciatic nerve and associated ganglia were removed five weeks after the first CDDP injection for biochemical evaluation of malondialdehyde (MDA) content and myeloperoxidase (MPO) activity, immunohistochemistry of terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL), TNF-α, caspase-3 and iNOS, and transmission electron microscopic (TEM) assessments., Results: MDA levels and MPO activities were significantly decreased in preconditioned rats. Attenuated TUNEL reaction along with attenuated caspase-3, TNF-α, and iNOS expression could be significantly detected in preconditioned rats. Also, HBO preconditioning improved the nociceptive threshold., Conclusion: The results suggest that HBO preconditioning can attenuate peripheral neuropathy caused by cisplatin in rats.
- Published
- 2020
- Full Text
- View/download PDF
13. Inhibition of H1N1 influenza virus infection by zinc oxide nanoparticles: another emerging application of nanomedicine.
- Author
-
Ghaffari H, Tavakoli A, Moradi A, Tabarraei A, Bokharaei-Salim F, Zahmatkeshan M, Farahmand M, Javanmard D, Kiani SJ, Esghaei M, Pirhajati-Mahabadi V, Monavari SH, and Ataei-Pirkooh A
- Subjects
- Microbial Sensitivity Tests, Nanomedicine, Antiviral Agents pharmacology, Influenza A Virus, H1N1 Subtype drug effects, Metal Nanoparticles, Polyethylene Glycols pharmacology, Zinc Oxide pharmacology
- Abstract
Background: Currently available anti-influenza drugs are often associated with limitations such as toxicity and the appearance of drug-resistant strains. Therefore, there is a pressing need for the development of novel, safe and more efficient antiviral agents. In this study, we evaluated the antiviral activity of zinc oxide nanoparticles (ZnO-NPs) and PEGylated zinc oxide nanoparticles against H1N1 influenza virus., Methods: The nanoparticles were characterized using the inductively coupled plasma mass spectrometry, x-ray diffraction analysis, and electron microscopy. MTT assay was applied to assess the cytotoxicity of the nanoparticles, and anti-influenza activity was determined by TCID50 and quantitative Real-Time PCR assays. To study the inhibitory impact of nanoparticles on the expression of viral antigens, an indirect immunofluorescence assay was also performed., Results: Post-exposure of influenza virus with PEGylated ZnO-NPs and bare ZnO-NPs at the highest non-toxic concentrations could be led to 2.8 and 1.2 log10 TCID50 reduction in virus titer when compared to the virus control, respectively (P < 0.0001). At the highest non-toxic concentrations, the PEGylated and unPEGylated ZnO-NPs led to inhibition rates of 94.6 and 52.2%, respectively, which were calculated based on the viral loads. There was a substantial decrease in fluorescence emission intensity in viral-infected cell treated with PEGylated ZnO-NPs compared to the positive control., Conclusions: Taken together, our study indicated that PEGylated ZnO-NPs could be a novel, effective, and promising antiviral agent against H1N1 influenza virus infection, and future studies can be designed to explore the exact antiviral mechanism of these nanoparticles.
- Published
- 2019
- Full Text
- View/download PDF
14. In Vitro Cytotoxicity of Folate-Silica-Gold Nanorods on Mouse Acute Lymphoblastic Leukemia and Spermatogonial Cells.
- Author
-
Eslahi N, Shakeri-Zadeh A, Ashtari K, Pirhajati-Mahabadi V, Tohidi Moghadam T, Shabani R, Kamrava K, Madjd Z, Maki C, Asgari HR, and Koruji M
- Abstract
Objective: The purpose of this study was to evaluate in vitro cytotoxicity of gold nanorods (GNRs) on the viability of spermatogonial cells (SSCs) and mouse acute lymphoblastic leukemia cells (EL4s)., Materials and Methods: In this experimental study, SSCs were isolated from the neonate mice, following enzymatic digestion and differential plating. GNRs were synthesized, then modified by silica and finally conjugated with folic acid to form F-Si-GNRs. Different doses of F-Si-GNRs (25, 50, 75, 100, 125 and 140 μM) were used on SSCs and EL4s. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) proliferation assay was performed to examine the GNRs toxicity. Flow cytometry was used to confirm the identity of the EL4s and SSCs. Also, the identity and functionality of SSCs were determined by the expression of specific spermatogonial genes and transplantation into recipient testes. Apoptosis was determined by flow cytometry using an annexin V/propidium iodide (PI) kit., Results: Flow cytometry showed that SSCs and EL4s were positive for Plzf and H-2kb, respectively. The viability percentage of SSCs and EL4s that were treated with 25, 50, 75, 100, 125 and 140 μM of F-Si-GNRs was 65.33 ± 3.51%, 60 ± 3.6%, 51.33 ± 3.51%, 49 ± 3%, 30.66 ± 2.08% and 16.33 ± 2.51% for SSCs and 57.66 ± 0.57%, 54.66 ± 1.5%, 39.66 ± 1.52%, 12.33 ± 2.51%, 10 ± 1% and 5.66 ± 1.15% for EL4s respectively. The results of the MTT assay indicated that 100 μM is the optimal dose to reach the highest and lowest level of cell death in EL4s and in SSCs, respectively., Conclusion: Cell death increased with increasing concentrations of F-Si-GNRs. Following utilization of F-Si-GNRs, there was a significant difference in the extent of apoptosis between cancer cells and SSCs., Competing Interests: There is no conflict of interest in this study., (Copyright© by Royan Institute. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
15. Comparative Effectiveness of a Technology-Facilitated Depression Care Management Model in Safety-Net Primary Care Patients With Type 2 Diabetes: 6-Month Outcomes of a Large Clinical Trial.
- Author
-
Wu S, Ell K, Jin H, Vidyanti I, Chou CP, Lee PJ, Gross-Schulman S, Sklaroff LM, Belson D, Nezu AM, Hay J, Wang CJ, Scheib G, Di Capua P, Hawkins C, Liu P, Ramirez M, Wu BW, Richman M, Myers C, Agustines D, Dasher R, Kopelowicz A, Allevato J, Roybal M, Ipp E, Haider U, Graham S, Mahabadi V, and Guterman J
- Subjects
- Comorbidity, Depression pathology, Diabetes Mellitus, Type 2 epidemiology, Diabetes Mellitus, Type 2 pathology, Diabetes Mellitus, Type 2 therapy, Female, Humans, Male, Patient Reported Outcome Measures, Quality of Health Care, Time Factors, Depression therapy, Diabetes Mellitus, Type 2 psychology, Primary Health Care organization & administration
- Abstract
Background: Comorbid depression is a significant challenge for safety-net primary care systems. Team-based collaborative depression care is effective, but complex system factors in safety-net organizations impede adoption and result in persistent disparities in outcomes. Diabetes-Depression Care-management Adoption Trial (DCAT) evaluated whether depression care could be significantly improved by harnessing information and communication technologies to automate routine screening and monitoring of patient symptoms and treatment adherence and allow timely communication with providers., Objective: The aim of this study was to compare 6-month outcomes of a technology-facilitated care model with a usual care model and a supported care model that involved team-based collaborative depression care for safety-net primary care adult patients with type 2 diabetes., Methods: DCAT is a translational study in collaboration with Los Angeles County Department of Health Services, the second largest safety-net care system in the United States. A comparative effectiveness study with quasi-experimental design was conducted in three groups of adult patients with type 2 diabetes to compare three delivery models: usual care, supported care, and technology-facilitated care. Six-month outcomes included depression and diabetes care measures and patient-reported outcomes. Comparative treatment effects were estimated by linear or logistic regression models that used generalized propensity scores to adjust for sampling bias inherent in the nonrandomized design., Results: DCAT enrolled 1406 patients (484 in usual care, 480 in supported care, and 442 in technology-facilitated care), most of whom were Hispanic or Latino and female. Compared with usual care, both the supported care and technology-facilitated care groups were associated with significant reduction in depressive symptoms measured by scores on the 9-item Patient Health Questionnaire (least squares estimate, LSE: usual care=6.35, supported care=5.05, technology-facilitated care=5.16; P value: supported care vs usual care=.02, technology-facilitated care vs usual care=.02); decreased prevalence of major depression (odds ratio, OR: supported care vs usual care=0.45, technology-facilitated care vs usual care=0.33; P value: supported care vs usual care=.02, technology-facilitated care vs usual care=.007); and reduced functional disability as measured by Sheehan Disability Scale scores (LSE: usual care=3.21, supported care=2.61, technology-facilitated care=2.59; P value: supported care vs usual care=.04, technology-facilitated care vs usual care=.03). Technology-facilitated care was significantly associated with depression remission (technology-facilitated care vs usual care: OR=2.98, P=.04); increased satisfaction with care for emotional problems among depressed patients (LSE: usual care=3.20, technology-facilitated care=3.70; P=.05); reduced total cholesterol level (LSE: usual care=176.40, technology-facilitated care=160.46; P=.01); improved satisfaction with diabetes care (LSE: usual care=4.01, technology-facilitated care=4.20; P=.05); and increased odds of taking an glycated hemoglobin test (technology-facilitated care vs usual care: OR=3.40, P<.001)., Conclusions: Both the technology-facilitated care and supported care delivery models showed potential to improve 6-month depression and functional disability outcomes. The technology-facilitated care model has a greater likelihood to improve depression remission, patient satisfaction, and diabetes care quality., (©Shinyi Wu, Kathleen Ell, Haomiao Jin, Irene Vidyanti, Chih-Ping Chou, Pey-Jiuan Lee, Sandra Gross-Schulman, Laura Myerchin Sklaroff, David Belson, Arthur M Nezu, Joel Hay, Chien-Ju Wang, Geoffrey Scheib, Paul Di Capua, Caitlin Hawkins, Pai Liu, Magaly Ramirez, Brian W Wu, Mark Richman, Caitlin Myers, Davin Agustines, Robert Dasher, Alex Kopelowicz, Joseph Allevato, Mike Roybal, Eli Ipp, Uzma Haider, Sharon Graham, Vahid Mahabadi, Jeffrey Guterman. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 23.04.2018.)
- Published
- 2018
- Full Text
- View/download PDF
16. In vitro differentiation of neural stem cells into noradrenergic-like cells.
- Author
-
Pirhajati Mahabadi V, Movahedin M, Semnanian S, Mirnajafi-Zadeh J, and Faizi M
- Abstract
Neural stem cells (NSCs) as a heterogeneous multipotent and self- renewal population are found in different areas in the developing mammalian nervous system, as well as the sub-ventricular zone (SVZ) and the hippocampus of the adult brain. NSCs can give rise to neurons, astrocytes and oligodendrocytes. The aim of this study was to differentiate neural stem cells into noradrenergic-like cells in vitro. Neural stem cells were harvested from SVZ of newborn rat brains. The cells were cultured in DMEM12, B-27 supplemented with 20 ng/ ml (hFGF) and 20 ng/ ml (EGF) for 2 weeks. Neurospheres were differentiated in neurobasal medium, B-27 supplemented with BDNF (50 ng/ ml) and GDNF (30 ng/ ml) for 3 and 5 days. Cell culture techniques and immunocytochemistry were applied to examine neurospheres and tyrosine hydroxylase positive cells. The number of neurites was counted 3 and 5 days after the induction of differentiation. Nestin and Sox2 were expressed in NSCs and neurospheres. NSCs were differentiated into noradrenergic- like cells (NACs). Tyrosine hydroxylase was detected in these cells. The results of NSCs differentiation for 5 days culture had a significant decrease (P≤0.05) in the number of TH positive cells with one or two neurite per cell, and a significant increase (P≤0.05) in the number of TH positive cells with three, four or more neurites per cell, compared with 3 days culture. Based on these results, NSCs have the ability to differentiate into noradrenergic cells in the presence of BDNF and GDNF growth factors.
- Published
- 2015
17. Promotion of remyelination by adipose mesenchymal stem cell transplantation in a cuprizone model of multiple sclerosis.
- Author
-
Hedayatpour A, Ragerdi I, Pasbakhsh P, Kafami L, Atlasi N, Pirhajati Mahabadi V, Ghasemi S, and Reza M
- Abstract
Objective: Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the central nervous system (CNS). Stem cell transplantation is a new therapeutic approach for demyelinating diseases such as MS which may promote remyelination. In this study, we evaluate the remyelinating potential of adipose mesenchymal stem cells (ADSCs) and their effect on neural cell composition in the corpus callosum in an experimental model of MS., Materials and Methods: This experimental study used adult male C57BL/6 mice. Cultured ADSCs were confirmed to be CD73(+),CD90(+), CD31(-),CD45(-), and labeled by PKH26. Animals were fed with 0.2% w/w cuprizone added to ground breeder chow ad libitum for six weeks. At day 0 after cuprizone removal, mice were randomly divided into two groups: the ADSCs-transplanted group and the control vehicle group (received medium alone). Some mice of the same age were fed with their normal diet to serve as healthy control group. Homing of ADSCs in demyelinated lesions was examined by fluorescent microscope. At ten days after transplantation, the mice were euthanized and their cells analyzed by luxol fast blue staining (LFB), transmission electron microscopy and flow cytometry. Results were analyzed by one-way analysis of variance (ANOVA)., Results: According to fluorescent cell labeling, transplanted ADSCs appeared to survive and exhibited homing specificity. LFB staining and transmission electron microscope evaluation revealed enhanced remyelination in the transplanted group compared to the control vehicle group. Flow cytometry analysis showedan increase in Olig2 and O4 cells and a decrease in GFAP and Iba-1 cells in the transplanted group., Conclusion: Our results indicate that ADSCs may provide a feasible, practical way for remyelination in diseases such as MS.
- Published
- 2013
18. 17β-Estradiol enhances the efficacy of adipose-derived mesenchymal stem cells on remyelination in mouse model of multiple sclerosis.
- Author
-
Ragerdi Kashani I, Hedayatpour A, Pasbakhsh P, Kafami L, Atlasi N, Pirhajati Mahabadi V, Mamoudi R, and Baazm M
- Subjects
- Animals, Basic Helix-Loop-Helix Transcription Factors metabolism, Calcium-Binding Proteins metabolism, Cell Differentiation, Cell Lineage, Cell Movement, Cells, Cultured, Combined Modality Therapy, Corpus Callosum metabolism, Corpus Callosum pathology, Cuprizone, Disease Models, Animal, Drug Implants, Estradiol administration & dosage, Flow Cytometry, Glial Fibrillary Acidic Protein metabolism, Male, Mice, Mice, Inbred C57BL, Microfilament Proteins metabolism, Multiple Sclerosis chemically induced, Multiple Sclerosis metabolism, Multiple Sclerosis pathology, Multiple Sclerosis physiopathology, Nerve Fibers, Myelinated metabolism, Nerve Fibers, Myelinated pathology, Nerve Tissue Proteins metabolism, Oligodendrocyte Transcription Factor 2, Time Factors, Adipose Tissue cytology, Corpus Callosum drug effects, Estradiol pharmacology, Mesenchymal Stem Cell Transplantation, Multiple Sclerosis therapy, Myelin Sheath metabolism, Nerve Fibers, Myelinated drug effects
- Abstract
Previous studies have demonstrated the potential of monotherapy with either mesenchymal stem cells (MSCs) or estrogen in autoimmune and cuprizone models of multiple sclerosis (MS). The aim of this study was to examine the effects of co-administration of 17β-estradiol (E2) and adipose-derived mesenchymal stem cells (ADSCs) on remyelination of corpus callosum axons in a cuprizone model of MS. Forty eight male C57BL/6 mice were fed cuprizone (0.2%) for 6 weeks. At day 0 after cuprizone removal, animals were randomly divided into four groups. The E2 monotherapy, ADSCs monotherapy, E2/ADSCs combined therapy and vehicle control. Some mice of the same age were fed with their normal diet to serve as healthy control group. E2 pellets, designed to release 5.0 mg E2 over 10 days, were implanted subcutaneously. 10(6) PKH26 labeled ADSCs were transplanted into lateral tail. The extent of demyelination, remyelination, and cell type's composition of host brain were examined at 10 days post-transplantation in the body of the corpus callosum. Transplanted cells migrated to the corpus callosum injury. Histological examination revealed efficacy of intravenous ADSCs transplantation in remyelination of mouse cuprizone model of MS can be significantly enhanced by E2 administration. Flow cytometry showed that the mean percentages of expression of Iba-1, Olig2 and O4 were significantly increased in E2/ADSCs combined therapy in comparison with ADSCs monotherapy. In conclusion, the findings of this study revealed that E2 administration enhanced efficacy of intravenous ADSCs transplantation in remyelination of corpus callosum axons in mouse cuprizone model of MS., (© 2012 Tehran University of Medical Sciences. All rights reserved.)
- Published
- 2012
19. Comparison of transplantation of bone marrow stromal cells (BMSC) and stem cell mobilization by granulocyte colony stimulating factor after traumatic brain injury in rat.
- Author
-
Bakhtiary M, Marzban M, Mehdizadeh M, Joghataei MT, Khoei S, Pirhajati Mahabadi V, Laribi B, Tondar M, and Moshkforoush A
- Subjects
- Animals, Bone Marrow Cells cytology, Brain Injuries surgery, Bromodeoxyuridine, Granulocyte Colony-Stimulating Factor administration & dosage, Immunohistochemistry, Injections, Subcutaneous, Male, Neurologic Examination, Nissl Bodies ultrastructure, Psychomotor Performance, Rats, Rats, Wistar, Staining and Labeling, Stromal Cells transplantation, Treatment Outcome, Bone Marrow Transplantation, Brain Injuries therapy, Granulocyte Colony-Stimulating Factor therapeutic use, Hematopoietic Stem Cell Mobilization, Mesenchymal Stem Cell Transplantation
- Abstract
Background: Recent clinical studies of treating traumatic brain injury (TBI) with autologous adult stem cells led us to compare effect of intravenous injection of bone marrow mesenchymal stem cells (BMSC) and bone marrow hematopoietic stem cell mobilization, induced by granulocyte colony stimulating factor (G-CSF), in rats with a cortical compact device., Methods: Forty adult male Wistar rats were injured with controlled cortical impact device and divided randomly into four groups. The treatment groups were injected with 2 × 106 intravenous bone marrow stromal stem cell (n = 10) and also with subcutaneous G-CSF (n = 10) and sham-operation group (n = 10) received PBS and "bromodeoxyuridine (Brdu)" alone, i.p. All injections were performed 1 day after injury into the tail veins of rats. All cells were labeled with Brdu before injection into the tail veins of rats. Functional neurological evaluation of animals was performed before and after injury using modified neurological severity scores (mNSS). Animals were sacrificed 42 days after TBI and brain sections were stained by Brdu immunohistochemistry., Results: Statistically, significant improvement in functional outcome was observed in treatment groups compared with control group (P<0.01). mNSS showed no significant difference between the BMSC and G-CSF-treated groups during the study period (end of the trial). Histological analyses showed that Brdu-labeled (MSC) were present in the lesion boundary zone at 42nd day in all injected animals., Conclusion: In our study, we found that administration of a bone marrow-stimulating factor (G-CSF) and BMSC in a TBI model provides functional benefits.
- Published
- 2010
20. Combined transdermal testosterone gel and the progestin nestorone suppresses serum gonadotropins in men.
- Author
-
Mahabadi V, Amory JK, Swerdloff RS, Bremner WJ, Page ST, Sitruk-Ware R, Christensen PD, Kumar N, Tsong YY, Blithe D, and Wang C
- Subjects
- Administration, Cutaneous, Adolescent, Adult, Contraception adverse effects, Contraceptive Agents, Male administration & dosage, Contraceptive Agents, Male adverse effects, Contraceptive Agents, Male pharmacology, Down-Regulation drug effects, Drug Combinations, Gels administration & dosage, Gels adverse effects, Gels pharmacology, Humans, Male, Middle Aged, Norprogesterones administration & dosage, Norprogesterones adverse effects, Progesterone Congeners administration & dosage, Progesterone Congeners adverse effects, Progesterone Congeners pharmacology, Sex Hormone-Binding Globulin analysis, Testosterone administration & dosage, Testosterone adverse effects, Young Adult, Contraception methods, Gonadotropins blood, Norprogesterones pharmacology, Testosterone pharmacology
- Abstract
Context: Testosterone (T) plus progestin combinations are the most promising hormonal male contraceptives. Nestorone (NES), a progestin without estrogenic or androgenic activity, when combined with T may be an excellent candidate for male contraception., Objective: Our objective was to determine the effect of transdermal NES gel alone or with T gel on gonadotropin suppression., Design and Setting: The randomized, unblinded clinical trial was conducted at two academic medical centers., Participants: A total of 140 healthy male volunteers participated., Interventions: One hundred subjects were randomized initially (20 per group) to apply NES gel 2 or 4 mg, T gel 10 g, or T gel 10 g plus NES gel 2 or 4 mg daily for 20 d. Because only about half of the subjects in T plus NES 4 mg group suppressed serum gonadotropins to 0.5 IU/liter or less (suboptimal suppression), two additional groups of 20 men were randomized to apply daily T gel 10 g plus NES gel 6 or 8 mg., Main Outcome Variable: Suppression of serum LH and FSH concentrations to 0.5 IU/liter or less after treatment was the main outcome variable., Results: A total of 119 subjects were compliant with gel applications with few study-related adverse events. NES alone reduced gonadotropins significantly but less than T gel alone. Combined T gel 10g plus NES gel 6 or 8 mg suppressed both serum gonadotropins to 0.5 IU/liter or less in significantly more men than either gel alone., Conclusion: Transdermal NES gel alone had gonadotropin suppression activity. Combined transdermal NES (6 or 8 mg) plus T gel demonstrated safe and effective suppression of gonadotropins, justifying a longer-term study of this combination for suppression of spermatogenesis.
- Published
- 2009
- Full Text
- View/download PDF
21. Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression.
- Author
-
Ma K, Mallidis C, Bhasin S, Mahabadi V, Artaza J, Gonzalez-Cadavid N, Arias J, and Salehian B
- Subjects
- Animals, Body Weight drug effects, Dexamethasone adverse effects, Dexamethasone antagonists & inhibitors, Dexamethasone pharmacology, Gene Expression Regulation drug effects, Kinetics, Male, Mifepristone pharmacology, Muscle, Skeletal pathology, Myostatin, Organ Size drug effects, RNA, Messenger analysis, Rats, Rats, Sprague-Dawley, Receptors, Glucocorticoid physiology, Glucocorticoids adverse effects, Muscle, Skeletal chemistry, Muscular Atrophy chemically induced, Transforming Growth Factor beta genetics
- Abstract
The mechanisms by which excessive glucocorticoids cause muscular atrophy remain unclear. We previously demonstrated that dexamethasone increases the expression of myostatin, a negative regulator of skeletal muscle mass, in vitro. In the present study, we tested the hypothesis that dexamethasone-induced muscle loss is associated with increased myostatin expression in vivo. Daily administration (60, 600, 1,200 micro g/kg body wt) of dexamethasone for 5 days resulted in rapid, dose-dependent loss of body weight (-4.0, -13.4, -17.2%, respectively, P < 0.05 for each comparison), and muscle atrophy (6.3, 15.0, 16.6% below controls, respectively). These changes were associated with dose-dependent, marked induction of intramuscular myostatin mRNA (66.3, 450, 527.6% increase above controls, P < 0.05 for each comparison) and protein expression (0.0, 260.5, 318.4% increase above controls, P < 0.05). We found that the effect of dexamethasone on body weight and muscle loss and upregulation of intramuscular myostatin expression was time dependent. When dexamethasone treatment (600 micro g. kg-1. day-1) was extended from 5 to 10 days, the rate of body weight loss was markedly reduced to approximately 2% within this extended period. The concentrations of intramuscular myosin heavy chain type II in dexamethasone-treated rats were significantly lower (-43% after 5-day treatment, -14% after 10-day treatment) than their respective corresponding controls. The intramuscular myostatin concentration in rats treated with dexamethasone for 10 days returned to basal level. Concurrent treatment with RU-486 blocked dexamethasone-induced myostatin expression and significantly attenuated body loss and muscle atrophy. We propose that dexamethasone-induced muscle loss is mediated, at least in part, by the upregulation of myostatin expression through a glucocorticoid receptor-mediated pathway.
- Published
- 2003
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.